Citation: | LIU Yifan, YANG Shengran, ZHOU Zhenxin, et al. Vaccine development and use for the elderly[J]. J China Pharm Univ, 2025, 56(3): 287 − 294. DOI: 10.11665/j.issn.1000-5048.2025022802 |
As an inevitable trend of social development, aging has generated a wide and far-reaching impact on every aspect of society, especially posing severe challenges for the heath system of all countries and regions around the world. Facing the objective reality of humans co-existing with diseases in a long term and people’s ever-growing demand for healthcare, the successful development of vaccine products can provide people with effective preventive measures to combat infectious diseases. This article summarizes the development and use of 4 vaccines that are suitable for the elder population, i.e., influenza vaccine, pneumococcal vaccine, varicella-zoster virus vaccine and respiratory syncytial virus vaccine, aiming to provide some reference for the development and popularization of these vaccines and to improve the well-being of the senior citizens.
[1] |
National Bureau of Statistics. Wang Pingping: population decline accompanied by progress in high-quality population development(王萍萍: 人口总量有所下降 人口高质量发展取得成效)[EB/OL]. (2024-01-18). https://www.stats.gov.cn/xxgk/jd/sjjd2020/202401/t20240118_1946711.html.
|
[2] |
Liu ZQ, Liang QM, Ren YQ, et al. Immunosenescence: molecular mechanisms and diseases[J]. Signal Transduct Target Ther, 2023, 8(1): 200. doi: 10.1038/s41392-023-01451-2
|
[3] |
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG. Technical guidelines for seasonal influenza vaccination in China (2023-2024)[J]. Chin J Epidemiol(中华流行病学杂志), 2023, 44(10): 1507-1530.
|
[4] |
Langer J, Welch VL, Moran MM, et al. High clinical burden of influenza disease in adults aged ≥ 65 years: can we do better?A systematic literature review[J]. Adv Ther, 2023, 40(4): 1601-1627. doi: 10.1007/s12325-023-02432-1
|
[5] |
Li L, Liu YN, Wu P, et al. Influenza-associated excess respiratory mortality in China, 2010-15: a population-based study[J]. Lancet Public Health, 2019, 4(9): e473-e481. doi: 10.1016/S2468-2667(19)30163-X
|
[6] |
Minozzi S, Lytras T, Gianola S, et al. Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis[J]. EClinicalMedicine, 2022, 46: 101331. doi: 10.1016/j.eclinm.2022.101331
|
[7] |
Vaccines against influenza WHO position paper–November 2012[J]. Wkly Epidemiol Rec, 2012, 87(47): 461-476.
|
[8] |
Dhanasekaran V, Sullivan S, Edwards KM, et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination[J]. Nat Commun, 2022, 13(1): 1721. doi: 10.1038/s41467-022-29402-5
|
[9] |
Koutsakos M, Wheatley AK, Laurie K, et al. Influenza lineage extinction during the COVID-19 pandemic[J]? Nat Rev Microbiol, 2021, 19(12): 741-742. doi: 10.1038/s41579-021-00642-4
|
[10] |
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season[EB/OL]. (2023-02-24). https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season.
|
[11] |
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season[EB/OL]. (2023-09-29). https://www.who.int/news/item/29-09-2023-recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season.
|
[12] |
Food and Drug Administration Center for Biologics Evaluation and Research. Summary minutes 183rd vaccines and related biological products advisory committee[EB/OL]. (2023-10-05). https://www.fda.gov/media/173654/download.
|
[13] |
Food and Drug Administration. FLUAD[EB/OL]. (2024-07-01). https://www.fda.gov/vaccines-blood-biologics/vaccines/fluad.
|
[14] |
Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects[J]. Eur J Epidemiol, 2001, 17(2): 135-140. doi: 10.1023/A:1017919305501
|
[15] |
Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010[J]. MMWR Morb Mortal Wkly Rep, 2010, 59(16): 485-486.
|
[16] |
Sanofi US News. FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older[EB/OL]. (2019-11-04). https://www.news.sanofi.us/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older.
|
[17] |
Balasubramani GK, Choi WS, Nowalk MP, et al. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19[J]. Vaccine, 2020, 38(42): 6562-6569. doi: 10.1016/j.vaccine.2020.08.011
|
[18] |
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults[J]. N Engl J Med, 2014, 371(7): 635-645. doi: 10.1056/NEJMoa1315727
|
[19] |
US CDC. Flu and people 65 years and older[EB/OL]. (2024-09-05). https://www.cdc.gov/flu/highrisk/65over.htm.
|
[20] |
Wang LJ, Huang WJ, Wang YC. Advances in the research and development of universal influenza vaccines[J]. China Food Drug Adm Mag(中国食品药品监管), 2023(5): 18-23.
|
[21] |
Active Bacterial Core surveillance (ABCs). ABCs report emerging infections program network Streptococcus pneumoniae, 2022[EB/OL]. (2024-07-05). https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2022.pdf.
|
[22] |
Fan GH, Zhou YC, Zhou F, et al. The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China[J]. Lancet Reg Health West Pac, 2023, 42: 100968.
|
[23] |
Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans[J]. Clin Microbiol Infect, 2012, 18(Suppl 5): 15-24.
|
[24] |
Wang XY. Evolution of pneumonia vaccines: combating the leading killer[J]. Grand Gard Sci(科学大观园), 2022(24): 24-27.
|
[25] |
Merck. Merck announces U. S. FDA approval of VAXNEUVANCE™ (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in adults 18 years and older caused by 15 serotypes[EB/OL]. (2021-07-16). https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/.
|
[26] |
Pfizer. U. S. FDA approves PREVNAR 20™, Pfizer’s pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older[EB/OL]. (2021-06-08). https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent.
|
[27] |
Merck. U. S. FDA Approves CAPVAXIVE™ (pneumococcal 21-valent conjugate vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults[EB/OL]. (2024-06-17). https://www.merck.com/news/u-s-fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults/.
|
[28] |
US CDC. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U. S. adults: updated recommendations of the advisory committee on immunization practices–United States, 2022[EB/OL]. (2022-05-13).https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm.
|
[29] |
US CDC. Use of 21-valent pneumococcal conjugate vaccine among U. S. adults: recommendations of the advisory committee on immunization practices–United States, 2024[EB/OL]. (2024-10-01). https://www.cdc.gov/mmwr/volumes/73/wr/mm7336a3.htm.
|
[30] |
Chinese Preventive Medicine Association, Vaccine and Immunology Branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version)[J]. Chin J Prev Med(中华预防医学杂志), 2020, 54(12): 1315-1363.
|
[31] |
Chen HY, Zhang T, Yang LB, et al. Retrospective cohort study on protective effect of 23-valent pneumococcal polysaccharide vaccine in elderly people[J]. Chin J Biol(中国生物制品学杂志), 2018, 31(8): 858-861.
|
[32] |
Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study[J]. Antimicrob Agents Chemother, 2012, 56(3): 1418-1426. doi: 10.1128/AAC.05658-11
|
[33] |
Weller TH, Stoddard MB. Intranuclear inclusion bodies in cultures of human tissue inoculated with Varicella vesicle fluid[J]. J Immunol, 1952, 68(3): 311-319. doi: 10.4049/jimmunol.68.3.311
|
[34] |
Chinese Society of General Practice, Chinese Medical Association Publishing House, Editorial Board of Chinese Journal of General Practitioners, et al. Expert consensus on vaccination against common infectious diseases in the community-dwelling elderly[J]. Chin J Gen Pract(中华全科医师杂志), 2022, 21(1): 6-23.
|
[35] |
Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management[J]. Viruses, 2022, 14(2): 192. doi: 10.3390/v14020192
|
[36] |
Zhang Z, Liu XN, Suo LD, et al. The incidence of herpes zoster in China: a meta-analysis and evidence quality assessment[J]. Hum Vaccin Immunother, 2023, 19(2): 2228169. doi: 10.1080/21645515.2023.2228169
|
[37] |
Cohen JI. Clinical practice: Herpes zoster[J]. N Engl J Med, 2013, 369(3): 255-263. doi: 10.1056/NEJMcp1302674
|
[38] |
Yu SY, Wan Y, Wan Q, et al. China expert consensus on diagnosis and treatment of postherpetic neuralgia[J]. Chin J Pain Med(中国疼痛医学杂志), 2016, 22(3): 161-167.
|
[39] |
Sun YW, Kim E, Kong CL, et al. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study[J]. Clin Infect Dis, 2021, 73(6): 949-956. doi: 10.1093/cid/ciab121
|
[40] |
CNN Money. FDA approves Merck’s Zostavax [EB/OL]. (2006-05-26). https://money.cnn.com/2006/05/25/news/companies/zostavax/index.htm.
|
[41] |
GSK. Shingrix approved in the US for prevention of shingles in adults aged 50 and over [EB/OL]. (2017-10-23). https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over/.
|
[42] |
BCHT. Herpes Zoster Vaccine, Live Vaccine Ganwei®(带状疱疹减毒活疫苗感维®)[EB/OL]. (2023-04-13). http://www.bchtpharm.com/Home/Article/detail/id/905.html.
|
[43] |
Harpaz R, Ortega-Sanchez IR, Seward JF Prevention of herpes zoster recommendations of the Advisory Committee on Immunization Practices (ACIP)[EB/OL].(2008-05-15). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm.
|
[44] |
US CDC. Shingles vaccination[EB/OL]. (2024-07-19). https://www.cdc.gov/shingles/vaccines/index.html.
|
[45] |
Li JL, Xu J. Research and application of herpes zoster vaccine[J]. J Microbes Infect(微生物与感染), 2020, 15(3): 186-191.
|
[46] |
Sanford M, Keating GM. Zoster vaccine (ZOSTAVAX): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults[J]. Drugs Aging, 2010, 27(2): 159-176. doi: 10.2165/10489140-000000000-00000
|
[47] |
Chinese Preventive Medicine Association. Diagnosis of human respiratory syncytial virus infection (CT/CPMA 028- 2023)[J]. Chin J Prev Med(中华预防医学杂志), 2023, 57(7): 961-967.
|
[48] |
Branche AR, Saiman LS, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020[J]. Clin Infect Dis, 2022, 74(6): 1004-1011. doi: 10.1093/cid/ciab595
|
[49] |
Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis[J]. Influenza Other Respir Viruses, 2023, 17(1): e13031. doi: 10.1111/irv.13031
|
[50] |
Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with Coryza[J]. Proc Soc Exp Biol Med, 1956, 92(3): 544-549. doi: 10.3181/00379727-92-22538
|
[51] |
Borchers AT, Chang C, Eric Gershwin M, et al. Respiratory syncytial virus: a comprehensive review[J]. Clin Rev Allergy Immunol, 2013, 45(3): 331-379. doi: 10.1007/s12016-013-8368-9
|
[52] |
GSK. US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults[EB/OL]. (2023-05-03). https://us.gsk.com/en-us/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/.
|
[53] |
Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults[J]. N Engl J Med, 2023, 388(7): 595-608. doi: 10.1056/NEJMoa2209604
|
[54] |
Pfizer. Pfizer’s ABRYSVO™ receives recommendation for use in older adults from Advisory Committee on Immunization Practices[EB/OL]. (2023-06-22). https://www.pfizer.com/news/announcements/pfizers-abrysvotm-receives-recommendation-use-older-adults-advisory-committee.
|
[55] |
Walsh EE, Marc GP, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults[J]. N Engl J Med, 2023, 388(16): 1465-1477. doi: 10.1056/NEJMoa2213836
|
[56] |
Moderna. Moderna Receives U. S. FDA approval for RSV vaccine mRESVIA(R)[EB/OL]. (2024-05-31). https://news.modernatx.com/news/news-details/2024/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR/default.aspx.
|
[57] |
Wilson E, Goswami J, Baqui AH, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults[J]. N Engl J Med, 2023, 389(24): 2233-2244. doi: 10.1056/NEJMoa2307079
|
[58] |
GSK. GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons[EB/OL]. (2024-10-08). https://us.gsk.com/en-us/media/press-releases/gsk-presents-positive-data-for-arexvy-indicating-protection-over-three-rsv-seasons/.
|
[59] |
CDC. RSV Vaccine Guidance for Older Adults[EB/OL]. (2024-08-30). https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html.
|
[60] |
Center for Drug Evaluation, NMPA. Implied license for clinical trials of respiratory syncytial virus vaccines(呼吸道合胞病毒疫苗临床试验默示许可)[EB/OL]. https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c.
|
[61] |
Orenstein WA, Offit PA, Edwards KM, et al. Plotkin's Vaccines[M]. 8th ed. Philadelphia: Elsevier, 2024.
|
[62] |
Kassianos G, Cohen JM, Civljak R, et al. The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from several European countries and Israel[J]. Expert Rev Respir Med, 2024, 18(3/4): 69-84.
|
[63] |
National Foundation for Infectious Diseases. Influenza vaccination coverage by population(2019-2023)[EB/OL]. (2023-09-28). https://www.nfid.org/resource/influenza-vaccination-coverage-by-population/.
|
[64] |
Cheng LX, Li L, Cao L, et al. Vaccination coverage of three non-EPI vaccines among the national population aged ≥60 years from 2019 to 2023[J]. China J Prev Med(中国预防医学杂志), 2024, 25 (5): 592-597.
Cheng LX, Li L, Cao L, et al. Vaccination coverage of three non-EPI vaccines among the national population aged ≥60 years from 2019 to 2023[J]. China J Prev Med(中国预防医学杂志), 2024, 25 (5): 592-597.
|
[65] |
UK Health Security Agency. Research and analysis pneumococcal polysaccharide vaccine(PPV): coverage report, England, April 2022 to March 2023[EB/OL]. (2024-05-01). https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates/pneumococcal-polysaccharide-vaccine-ppv-coverage-report-england-april-2022-to-march-2023.
|
[66] |
US CDC. Vaccination coverage among adults in the United States, national health interview survey, 2021[EB/OL]. (2024-07-19) https://www.cdc.gov/adultvaxview/publications-resources/vaccination-coverage-adults-2021.html
|
[67] |
Bai YH, Bai P, Li SP, et al. A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population[J]. Hum Vaccin Immunother, 2022, 18(6): 2139123. doi: 10.1080/21645515.2022.2139123
|
[68] |
Yamada N, Nakatsuka K, Tezuka M, et al. Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE study[J]. Vaccine, 2024, 42(2): 239-245. doi: 10.1016/j.vaccine.2023.12.009
|
[69] |
Vaccine MKT. Herpes zoster vaccine: addressing the needs of the elderly population (带状疱疹疫苗, 关注老年群体需求)[EB/OL]. (2022-12-25). https://mp.weixin.qq.com/s/t5_qen8Ui96imGe-zfeZ0g
|
[1] | Studies on the Antitussive and Antiasthmatic Film[J]. Journal of China Pharmaceutical University, 2000, (6): 26-28. |
[2] | Antihyperlipidemia and Anticoagulation Action of the Xinanning[J]. Journal of China Pharmaceutical University, 1997, (4): 47-50. |
[3] | Anti-inflammatory Effect of Aqueous Extract of Wu-Hu-Tang[J]. Journal of China Pharmaceutical University, 1995, (6): 362-364. |
[4] | Studies on the Antiendotoxic Action of Radix isatidis[J]. Journal of China Pharmaceutical University, 1995, (5): 297-299. |
[5] | Studies on Antitussive Action of Puqietinone[J]. Journal of China Pharmaceutical University, 1993, (2): 95-97. |
[6] | Cytoprotection Action of the Polysaccharide from Auricularia Polytricha Sacc[J]. Journal of China Pharmaceutical University, 1991, (5): 305-307. |
[7] | Anticoagulation and Antihyperlipidemia Action of the Polysaccharide from Auricularia Polytricha[J]. Journal of China Pharmaceutical University, 1991, (3): 164-166. |
[8] | Antifertility Action of Auricularia auricula Polysaccharide[J]. Journal of China Pharmaceutical University, 1991, (1): 48-49. |
[9] | STUDY ON ANTIFERTILITY ACTION OF MURRAYA PANICULATA EXTRACT[J]. Journal of China Pharmaceutical University, 1987, (3): 213-215. |
[10] | Dai Dezai, Liu Guoqing, Wu Huiqiu, Xie Lin, Ma Junru. Studies on the Central Locus of Anesthetic Action Induced by Scopolaimine[J]. Journal of China Pharmaceutical University, 1980, (2): 33-38. |